Nikkei English News - Jul. 25, 2008 ZURICH -(Dow Jones)- The European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) Friday said adopted positive opinions, recommending the granting of a marketing authorisation, for the following medicines. New medicinal products * Evicel (human fibrinogen / human thrombin), from Omrix Biopharmaceuticals S.A., fibrin sealant for use as supportive treatment in surgery where standard surgical techniques are insufficient. EMEA review began on 15 August 2007 with an active review time of 207 days. * Xarelto (rivaroxaban), from Bayer Health Care, for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery. ... To continue reading the complete article, login or register below and get free instant access. The...
[read full story]